The tumor suppressor Rb (retinoblastoma protein) is known to regulate p53-dependent apoptosis, but the mechanisms involved are unclear. In a rat fibroblast model, we previously observed that caspase inhibition potentiates p53-dependent apoptosis and prevents the Rb cleavage associated with p53 activation. These results suggested that a caspase(s) can antagonize p53-mediated apoptosis via the production of a protective Rb truncated form. Here, we identify caspase-9 as the caspase that interferes, upstream of the mitochondrion, with p53-induced apoptosis in both immortalized and primary fibroblasts. This caspase can be detected as a p38 processed form in living cells, in the absence of apoptosome formation and apoptotic signal. We also provide evidence that the involvement of caspase-9 in a premitochondrial protective pathway results from the previously undescribed cleavage of Rb, at a LExD site, into a p76
Introduction
Programmed cell death by apoptosis is an essential mechanism for proper tissue development, maintenance of tissue homeostasis and for the elimination of unwanted cells. Failure to initiate apoptosis of cells containing damaged DNA has been implicated in various cancers (Symonds et al., 1994; Evan and Littlewood, 1998) . Conversely, increased apoptosis is associated with diseases such as neurodegenerative disorders (Thompson, 1995) . The central component of the apoptotic machinery is a set of cysteine proteases called caspases that cleave their substrates after specific aspartate residues. Two canonical pathways of caspase activation have been described (Kaufmann and Hengartner, 2001) . One is initiated at the plasma membrane by ligand binding to receptors of the tumor necrosis factor receptor family. Upon ligation, death receptors cluster and form protein complexes on their cytoplasmic domain directly or indirectly (Micheau and Tschopp, 2003) , resulting in activation of caspase-8, an upstream caspase responsible for activating the effector caspases. In the second pathway, diverse stimuli promote mitochondrial outer membrane permeabilization and the release of caspase-activating factors, such as cytochrome c, from the mitochondria to the cytosol. Once cytochrome c is released, it associates with Apaf-1 and procaspase-9 to form the apoptosome complex, which facilitates the autoprocessing of the initiator caspase-9. Subsequently, activated caspase-9 cleaves downstream executioner caspases, such as caspase-3, -6 and -7. In turn, caspase-3 fully processes caspase-9 via a feedback loop leading to amplification of the apoptotic signal and cell degradation.
One of the important regulators of cell death is the tumor suppressor p53 which can induce cell cycle arrest or apoptosis in response to a variety of stresses, including DNA damage, oncogene activation and hypoxia. The p53 gene is mutated in more than 50% of human tumors, and in many others cancers, the p53 protein is indirectly inactivated through binding to viral oncoproteins or deregulated cellular proteins (Vogelstein et al., 2000) . Several studies show that caspases play a crucial role in p53-mediated apoptosis. Among these proteases, caspase-3 and caspase-8 have been shown to be activated upon p53 induction in different murine cell systems (Chandler et al., 1997; Cregan et al., 1999; Ding et al., 2000) . Caspase-9 and its cofactor Apaf-1 have been found to be essential components in Myc-induced apoptosis acting downstream of p53 (Soengas et al., 1999) . Release of cytochrome c has been demonstrated in response to p53-triggered apoptosis in different cell systems (Schuler et al., 2000; Gao et al., 2001 ). The retinoblastoma protein (Rb) is another tumor suppressor known to functionally interact with p53 in control of cell cycle and tumor development (reviewed in Dyson, 1998) . Abolition of Rb function, in cultured cells or animals, results in apoptosis involving both p53-dependent and -independent pathways. Rb exerts its antiapoptotic function, at least in part, by antagonizing p53 apoptotic activity at multiple levels (Macleod, 1999) . Similarly, ectopic expression of functional Rb in HeLa cells protects them from apoptosis induced by overexpression of wild-type p53 (Haupt et al., 1995) . The transcription factor E2F1 was proposed to be one of the possible links between Rb and p53. Indeed, free E2F1 can transcriptionally activate p19 ARF , which stabilizes p53 by inhibiting the function of its regulator MDM2 and consequently induces p53-dependent apoptosis (Pomerantz et al., 1998) . Overexpression of Rb, which leads to a sequestration of E2F1, can inhibit apoptosis induced by p53, therefore leading to the paradigm that Rb antagonizes p53-dependent apoptotic pathway. However, the growing number of reports demonstrating the involvement of Rb as an inducer of cell death point to a controversial role for this protein in apoptosis (Bowen et al., 1998; Knudsen et al., 1999; Slinskey et al., 1999) .
During apoptosis, Rb was shown to be cleaved by caspases, either at a C-terminal caspase-3-like consensus site generating a p100 form lacking 42 aa (Janicke et al., 1996; Chen et al., 1997; Boutillier et al., 2000) , or at an internal cleavage site producing two fragments of 68 and 48 kDa (An and Dou, 1996; Chen et al., 1997) . The internal site was shown to be cleaved by the executioner caspase-3 or -7 upon etoposide-induced apoptosis of Jurkat cells (Fattman et al., 2001) . Interestingly, it has been shown that the combination of IL-3 withdrawal and exposure to ionizing radiation induces rapid p53-dependent apoptosis accompanied by caspase-mediated cleavage of the Rb protein (Gottlieb and Oren, 1998) . However, whether the different truncated forms of Rb play a key role in apoptosis or are only a side effect of cell dismantling remains unclear.
We previously showed, in a rat embryo fibroblast model expressing a temperature-sensitive mutant of the SV40 Large T protein (LT), that LT inactivation leads to p53-mediated apoptosis (Zheng et al., 1994) . We also reported that bcl-2 overexpression prevents commitment to cell death (Guenal et al., 1997) . In contrast, zVADmediated caspase inhibition accelerates apoptosis, triggering an alternative apoptotic program, and abolishes the protective effect of Bcl-2 (Rincheval et al., 1999) . In addition, we observed that a truncated form of the tumor suppressor protein Rb strongly accumulates in the presence of Bcl-2 and that addition of zVAD prevents Rb cleavage. These data led us to postulate that one or more caspases could be involved in a protective regulatory pathway through the generation of a truncated form of Rb which would inhibit the apoptotic function of p53. In the present study, we identify caspase-9 as the zVAD-sensitive caspase that delays p53-induced apoptosis in both immortalized and primary fibroblasts. This caspase can be detected in living cells as a processed and active form in the absence of apoptosome formation or apoptotic stimuli. Moreover, we show that caspase-9 can produce the p76 Rb truncated form of Rb, which antagonizes p53-mediated apoptosis.
Results

Inhibition of caspase-9 increases p53-dependent apoptosis of REtsAF cells
We previously showed in a rat embryo fibroblast model (REtsAF cells) that inactivation of Large T antigen at 39.51C leads to p53-induced apoptosis (Zheng et al., 1994) that can be inhibited by Bcl-2 at the mitochondrial level (Guenal et al., 1997) . Surprisingly, we observed that the broad-spectrum caspase inhibitor zVAD accelerates cell death and totally abolishes the protection conferred by Bcl-2 ( Figure 1a , left panel and Rincheval et al., 1999) . Moreover, we demonstrate that apoptosis induced at 39.51C, both in the absence or presence of zVAD, required p53 activation (Godefroy et al., 2004) . These results strongly suggest that a zVAD-sensitive caspase could negatively regulates p53-dependent apoptosis. We then tried to identify the caspase that could be involved in this protective pathway. Catalytically inactive forms of either initiator (i.e. caspase-8 and -9) or executioner caspases (i.e. caspase-3 and -7), acting as dominant-negative mutants, were transiently transfected in order to specifically inhibit the activity of each of these proteases (Forcet et al., 2001 ). Among the mutants tested, DN caspase-3 and -8 partially protected cells against apoptosis, in accordance with the previously described role of these caspases in p53-mediated apoptosis ( Figure 1a ). In contrast, the caspase-9 mutant significantly increased apoptosis as observed with the peptide inhibitor zVAD. Since this mutant efficiently inhibits caspase-9 (Fearnhead et al., 1998; LopezHernandez et al., 2004) , our results suggest that caspase-9 activity can negatively regulate apoptosis triggered by p53 activation. Since this caspase is classically involved in the post-mitochondrial phase of p53-mediated apoptosis, we studied the status of this protease by Western blot analysis in our system. Rat caspase-9 can be alternatively cleaved at different aspartic residues to yield either a 38 kDa subunit described as autoprocessed caspase-9 (p38) or a 40 kDa and a 17 kDa subunit considered as the product of the processing of caspase-9 by caspase-3 (Srinivasula et al., 1998; Fujita et al., 2001) . Figure 1b shows that in control cell lysates without bcl-2 overexpression (331C ÀBcl-2), the p38 form of caspase-9 is detected, indicating that caspase-9 autoprocessing can occur in proliferating control cells in the absence of apoptotic signal. At the restrictive temperature (39.51C ÀBcl-2), caspase-3 activation, indicated by PARP cleavage, is accompanied by the cleavage of caspase-9 into p40 and p17 subunits. The faint cleavage of PARP correlates well with the slight protective effect of the DN caspase-3 mutant. We previously reported that apoptosis triggered by p53 involves Bax relocalization, cytochrome c release and apoptosome formation (Godefroy et al., 2004) . Consequently, as demonstrated in many other systems, caspase-9 is involved in the post-mitochondrial events triggered by p53 activation during REtsAF cell apoptosis. We also demonstrated that in REtsAF-Bcl-2 cells, bcl-2 overexpression precludes the mitochondrial changes normally observed at 39.51C and inhibits cytochrome c release, apoptosome formation and subsequent caspase-3 activation (Guenal et al., 1997; Godefroy et al., 2004) . Therefore, forced expression of bcl-2 allowed us to examine the effects of p53 activation on caspase-9 processing that take place upstream of the mitochondrion. As depicted in Figure 1b , bcl-2 overexpression prevented both caspase-3 activation, as demonstrated by the absence of PARP cleavage, and generation of p17 and p40 fragments (compare lane 39.51C ÀBcl-2 to lane 39.51C þ Bcl-2) but increased the accumulation of the autoprocessed 38 kDa form (compare lane 331C to lane 39.51C þ Bcl-2). Unexpectedly, this sustained accumulation of p38 observed in the presence of Bcl-2 suggests that autoprocessing of caspase-9 is independent of apoptosome formation, contrary to what was reported for other models. In contrast, inhibition of caspases by zVAD, which abrogates Bcl-2 protection, almost totally inhibited the production of the p38 form of caspase-9 (39.51C þ Z þ Bcl-2). Western blot analyses revealed that the p38 form present in control cells is produced at a higher level when apoptosis is inhibited by Bcl-2 and that the abolition of Bcl-2 protection by zVAD is accompanied by inhibition of p38 generation. Altogether these data suggest that in contrast to the mainly admitted proapoptotic role of caspase-9 (Shi, 2002) , in some circumstances, the p38 form of caspase-9 could be involved in a Bcl-2-mediated protective pathway, independently of apoptosome formation.
We next examined whether this unexpected role of caspase-9 could be observed in p53-independent apoptosis. Cells were transiently transfected with plasmids encoding p53 wt , p53 phe132 (a nontemperature-sensitive mutant) or Bcl-2 and treated for 6 h in the presence of staurosporine (STS) (Figure 2a ). While Bcl-2 greatly protected cells, expression of p53 showed no effect in STS-induced apoptosis. Moreover, no modification of the level of Bax, p21 and MDM2 proteins could be observed when apoptosis was triggered by STS, in contrast to the accumulation observed after p53 activation (39.51C). The accumulation of the cleaved form of PARP observed at 39.51C was more pronounced in STS-treated cells (Figure 2b ). Altogether, these results demonstrate that in REtsAF cells, STS induces a p53-independent apoptotic pathway that leads to activation of executioner caspases. To test the ability of caspase-9 to interfere with p53-independent apoptosis, the effect of DN caspase mutants was assessed on STS-induced death and results are presented on Figure 2c . As expected (Fujita et al., 2001) , the caspase-7 and -9 mutants inhibited apoptosis, indicating that in p53-independent apoptosis of REtsAF cells, caspase-9 is uniquely involved in the post-mitochondrial apoptosome formation which leads to caspase-7 activation and subsequent PARP cleavage.
Taken together, our results demonstrate a dual role for caspase-9 in p53-mediated apoptosis: (i), a proapoptotic function, downstream of the mitochondrion, in the apoptosome formation and the activation of executioner caspases and (ii) upstream of the mitochondrion, a role in a protective pathway stimulated by Bcl-2, which appears to be independent of apoptosome formation.
Role of caspase-9 in p53-dependent apoptosis of primary rat fibroblasts
We set forth to control whether zVAD and caspase-9 could similarly regulate p53-dependent apoptosis in the more physiological model of primary rat embryo Rb mediates caspase-9 antiapoptotic activity C Lemaire et al p53-dependent apoptosis in REF cells, which can be inhibited by Bcl-2. This apoptosis is increased in the presence of zVAD, while this inhibitor greatly reduced STS-induced p53-independent apoptosis ( Figure 3b ). Thus, in primary rat fibroblasts, as demonstrated with the REtsAF-Bcl-2 cell line, inhibition of caspases accelerates p53-dependent apoptosis, whereas it inhibits p53-independent cell death. To investigate the role of caspases, REFs were transiently transfected with caspase mutants and treated with either etoposide (Figure 3c ) or STS ( Figure 3d ). In Figure 3c , the protection conferred by DN caspase-3 and -8 mutants suggests that these two caspases can contribute to etoposide-induced apoptosis. The processing of caspase-3 revealed by Western Blot analysis further demonstrated the involvement of caspase-3 in etoposideinduced apoptosis (Figure 3e ). In contrast, in the presence of the DN caspase-9 mutant, extensive cell death was observed (165.7% of control) arguing in favor of the involvement of caspase-9 in a pathway that antagonizes p53-induced apoptosis. When exposed to STS, REFs were protected by both caspase-7 and -9 DN mutants (22.5 and 35.8% of control, respectively), thereby demonstrating the essential role of these two caspases in STS-induced cell death. Processing of caspase-9 is presented in Figure 3e . In the absence of apoptotic treatment (control), caspase-9 was detected in REF cells in its full length and processed p38 forms. When p53-dependent apoptosis was induced by etoposide, caspase-9 was almost fully processed to its p17 subunit. These results are similar to those obtained in REtsAF-Bcl-2 cells which did not overexpress bcl-2: (i) the p38 form of caspase-9 is produced in control cells, (ii) caspase-9 is fully processed in response to p53-dependent signal. These results provide direct evidence that the data observed in REtsAF cells are physiologically relevant and strongly suggest that in rat primary fibroblast caspase-9 can antagonize p53.
Identification of the caspase involved in Rb cleavage and p76 Rb production
Since the tumor suppressor Rb and p53 signaling pathways interact to regulate cell growth and apoptosis, we previously examined the status of Rb in p53-dependent apoptosis. We reported that in addition to the full-length Rb (105/110 kDa) and the C-terminal truncated (p100) forms described by others (Janicke et al., 1996; Chen et al., 1997) , an internally truncated form of Rb was detected in REtsAF-Bcl-2 cells at both permissive and restrictive temperature (Rincheval et al., 1999) . This form, initially named p68 according to its electrophoretic mobility, is now termed p76 Rb on the basis of the sequence-calculated molecular weight. The different forms of Rb accumulated with time at 39.51C and their production was more sustained in the presence of Bcl-2 (Figure 4a ). The broad-spectrum caspase inhibitor zVAD completely inhibited production of p76
Rb and allowed accumulation of the full-length Rb form (Figure 4b) . In REF cells, the production of p76 Rb was also observed (Figure 4c ). In the presence of etoposide, p53 activation increased the accumulation of p76
Rb while zVAD almost totally inhibited its generation, as observed in REtsAF-Bcl-2 cells. Our results demonstrate that a truncated form of Rb (p76 Rb mediates caspase-9 antiapoptotic activity C Lemaire et al rat Rb is shorter than its human homolog (bottom of Figure 5a ). Several studies have shown that hRb is cleaved at the executioner caspase consensus site DEAD 886 during apoptosis, leading to a protein product termed p100 (Janicke et al., 1996; Chen et al., 1997; Boutillier et al., 2000) . Moreover, a study by Fattman et al. (2001) reports that executioner caspase-3 and -7
can cleave hRb at the DSID 349 site to generate two fragments of 68 and 48 kDa. To our knowledge, there is no data showing cleavage at the LExD site. In our experiments, we used the G3-245 antibody, which recognizes either the N-ter fragment cleaved at DxID (p48) or the C-ter product of Rb cleaved at LExD (p76 Rb ) (Figure 5a ). Therefore, the results shown in Figure 4 suggest that the p76 Rb form, detected by the G3-245 antibody, could correspond to the Rb cleavage at LExD site. Since this site fits the consensus cleavage site of caspase-9 (LEHD), we tested the ability of this caspase to directly cleave recombinant Rb. We used two antibodies to clearly distinguish the different truncated products of hRb. The G3-245 antibody mentioned above and the Ab-6 antibody, which recognizes the Cter fragment, cleaved at LExD (p76 Rb ) or DxID (p68). These two antibodies also recognize the fragment truncated at the DEAD site (p100). The effects of initiator (caspase-2, -8, -9 and -10) and executioner (caspase-3, -6 and -7) caspases on hRb cleavage were first compared using the G3-245 antibody (upper panel of Figure 5b ). As expected, caspase-2, -3 and -7 cleaved the C-ter DEAD 886 site that fit the consensus site for these enzymes. The generation of the p48 fragment (Nterminal portion of hRb cleaved at the DSID 349 site) indicates that caspase-3 and to a lesser extent caspase-7 and -8 cleave hRb at the DSID 349 site. Among the caspases tested, only caspase-9 is efficient in generating p76
Rb by cleavage at the LEND 270 site in vitro. When blots were reprobed with Ab-6 antibody, cleavage of full-length hRb at the DSID 349 site by caspase-3 and -8 was confirmed by apparition of the p68 form (Figure 5b , lower panel). In addition, accumulation of the p61 fragment showed that hRb protein was mostly cleaved at both DSID 349 and DEAD 886 in the presence of executioner caspase-3 and -7. One can also note that, under our experimental conditions, caspase-6 and -10 partially cleaved hRb at DSID 349 . Our data corroborate the previously reported observations concerning cleavage of hRb by executioner caspase-3 and -7 (Chen et al., 1997; Boutillier et al., 2000; Fattman et al., 2001) . Moreover, we also present evidence that cleavage by caspase-9 occurs at the internal LExD site, allowing generation of the yet uncharacterized p76
Rb truncated form.
We next investigated the effect of whole-cell extracts from the REtsAF-Bcl2 cell line on hRb cleavage and (Figure 5c ). When hRb was incubated with control extract (lane 331C ÀBcl-2), a faint band corresponding to p76
Rb was detected. As observed for endogenous Rb (Figure 4a) , lysates of cells overexpressing antiapoptotic Bcl-2 protein increased production of p76
Rb (lane 331C þ Bcl-2). Incubation of hRb with lysates from cells cultured at 39.51C led to extensive accumulation of p76
Rb independent of the Bcl-2 protein. The ability of endogenous caspase-9 to cleave Rb was tested using specific caspase inhibitors. Similar results were obtained in the absence or in the presence of Bcl-2. Whole-cell extracts of REtsAF-Bcl-2 cultured at 39.51C with the broad-spectrum caspase inhibitor zVAD (39.51C þ Z) weakly cleaved hRb, further demonstrating the role of cellular caspases in p76
Rb production. In the presence of lysates obtained from cells in which caspase-9 was inhibited by the irreversible inhibitor LEHD (39.51C þ L), the amount of p76
Rb was significantly reduced compared to lysates of cells cultured at 39.51C without caspase inhibitor. As a control, the caspase-1-like inhibitor YVAD demonstrated that this family of caspases is unable to generate p76 Rb (39.51C þ Y). These results further confirm the ability of caspase-9 to generate p76
Rb by cleavage of Rb at the LExD site. Taken together, these results provide direct evidence that caspase-9 is the only caspase among the tested caspases responsible for internal cleavage of Rb protein at the LExD site and able to produce p76
Rb .
Effects of p76
Rb overexpression on p53-dependent apoptosis of rat fibroblasts
The above results indicated that caspase-9 can both cleave Rb to p76 Rb protein and antagonize p53-dependent apoptosis. We thus wished to find out whether p76
Rb could mediate the activity of caspase-9. For this purpose, vectors encoding full-length Rb or the truncated p76
Rb protein were constructed and transiently transfected in REtsAF cells. The ability of Rb vectors to regulate p53-dependent apoptosis was compared to that of plasmids encoding Bcl-2 and the DN p53 ala143 mutant. In the absence of zVAD, p76 Rb overexpression greatly decreased p53-dependent apoptosis (36.5% of control) to the same degree as Bcl-2 (35.5% of control) and the p53 ala143 mutant (34.1% of control) (Figure 6a, left panel) . In contrast, full-length Rb Rb mediates caspase-9 antiapoptotic activity C Lemaire et al exhibited no significant protective effect. The right panel of Figure 6a shows the result of a typical transfection experiment. After 20 h at 39.51C, round and blebbing cells were scored as apoptotic, while cells spread out were counted as living cells. The low proportion of apoptotic cells observed after p76
Rb overexpression clearly demonstrated the protective effect of this truncated form in contrast with full-length Rb. While the protection afforded by Bcl-2 overexpression was totally abrogated by zVAD, a significant reduction of apoptosis was allowed by forced expression of p76 Rb (63.4% of control) and the p53 ala143 mutant (60.5% of control), suggesting that p76
Rb acts downstream of the zVAD-sensitive caspase which antagonizes p53-dependent apoptosis.
Since p76 Rb can be produced by caspase-9 and can inhibit p53-dependent apoptosis, we postulated that it should decrease apoptosis even when caspase-9 is inhibited. REtsAF cells were therefore transfected with vectors encoding the DN caspase-9 mutant and the effect of either full-length Rb or p76
Rb on apoptosis was assessed ( Figure 6b, left panel) . The increase in p53-dependent apoptosis observed with DN caspase-9 mutant (163.7% of control) was not modified by the overexpression of full-length Rb (166.1% of control). In contrast, p76
Rb totally inhibited apoptosis induced by the DN caspase-9 mutant (101.3% of control). This protection is clearly visualized in the experiment presented in the right panel of Figure 6b , where fewer apoptotic cells were observed in the presence of p76 Rb (DN C9 vs DN C9 þ p76). Thus, in p53-dependent apoptosis, the p76
Rb truncated form of Rb acts downstream of caspase-9 and exerts an antiapoptotic function in REtsAF cell line. Since caspase-9 was also shown to antagonize p53-dependent apoptosis upstream of mitochondria in primary REFs (Figure 3c ), we wished to determine if the antiapoptotic activity of p76
Rb could be also found in REFs. Cells were transiently transfected with the vectors encoding one of the following proteins: Bcl-2, p53 wt , p53 ala143 , full-length Rb or p76
Rb . Etoposide was then added to transfected REFs to induce p53-dependent apoptosis. As previously described (Figure 3b) , overexpression of p53 wt stimulates apoptosis, whereas Bcl-2 and the DN p53 ala143 mutant protected cells from death. In the presence of Rb vectors, similar results were obtained in primary REFs as in the REtsAF cell line: while full-length Rb slightly increased the percentage of dead cells, p76 Rb overexpression decreased apoptosis showing again that this truncated form of Rb can counteract the p53-dependent apoptotic process (Figure 6c , right panel). Is p76
Rb involved in the protective pathway regulated by caspase-9 in REFs too? To answer this question, we tested the ability of p76
Rb to attenuate etoposide-dependent apoptosis induced by the DN caspase-9 mutant. Figure 6d clearly demonstrates that p76 Rb , as opposed to full-length Rb, abolished the death induced by inhibition of caspase-9 in primary cells (Figure 6d, left panel) . The protection conferred by p76
Rb can be visualized in the images presented in the right panels of Figure 6c and d. These data suggest that p76 Rb , which can be generated by caspase-9, antagonizes p53-dependent apoptosis of rat fibroblasts.
Discussion
In the present study, we have investigated the involvement of caspases and Rb protein in p53-dependent apoptosis of rat fibroblasts. We previously reported that instead of preventing cell death as observed in many models, the broad-spectrum caspase inhibitor zVAD greatly increases p53-dependent apoptosis, completely abolishes Bcl-2 protection and also inhibits Rb cleavage which is associated with p53 activation in this cellular model. These results suggested the existence of a caspase(s) which may promote cell survival via the production of an antiapoptotic Rb truncated form (Rincheval et al., 1999) . Here, we demonstrate that caspases-9 is a zVAD-sensitive caspase that can be involved in a protective pathway that antagonizes p53-dependent apoptosis upstream of mitochondrion. We also report that the truncated form of Rb, p76
Rb , mediates caspase-9 protective activity by negatively regulating p53-dependent apoptosis of rat fibroblasts.
Caspase 9 can antagonize p53-mediated apoptosis upstream of mitochondria
We demonstrate here that the unusual proapoptotic effect of zVAD observed in immortalized REtsAF-Bcl-2 cells (Rincheval et al., 1999) has a physiological significance since it can be reproduced in early-passage primary REF cells. To identify which zVAD-sensitive caspase could play a role in cell survival, initiator or executioner caspases commonly involved in apoptosis were specifically inhibited with dominant negative caspase mutants. We observe that DN caspase-3 and -8 mutants decrease p53-dependent apoptosis of REtsAF and primary REF cells, in agreement with other reports (Chandler et al., 1997; Cregan et al., 1999; Ding et al., 2000) . We also demonstrate that caspase-9 antagonizes p53-dependent apoptosis at a pre-mitochondrial stage, this effect appearing potentiated by the antiapoptotic protein Bcl-2. The caspase-9 is usually considered a major initiator caspase of cell death cascades in diverse apoptotic paradigms (Zheng et al., 1999) and it was found to be an essential downstream proapoptotic component of p53-induced cell death signaling (Soengas et al., 1999) . In agreement, we observed that caspase-9 acts as a proapoptotic protease in p53-independent apoptosis induced by STS or in the post-mitochondrial phase of p53-triggered apoptosome formation. Our findings thus point to an alternative involvement of caspase-9 in a protective pathway that inhibits p53-mediated apoptosis upstream of mitochondria in rat fibroblasts. Following p53 activation, four different forms of caspase-9 were detected in RetsAF-Bcl-2 and REF cells: the procaspase-9 form (51 kDa), the autoprocessed p38 form and the caspase-3-processed p40 and p17 subunits. We observed that upon p53 activa-tion, in the absence of Bcl-2, caspase-9 is processed by activated caspase-3 in a feedback loop and acts as an initiator of the proteolytic caspase cascade leading to the degradation phase of apoptosis. In contrast to the p40 and p17 subunits, the p38 form is found in proliferating control cells, accumulates in the presence of Bcl-2 and is inhibited by zVAD. These results suggest the existence of an apoptosome-independent alternative mechanism for caspase-9 activation as recently described in MEF cells (Bitzer et al., 2002) . Therefore, it is tempting to assume that the p38 form could be involved in a Bcl-2-regulated pathway that antagonizes p53. However, we cannot exclude that this function could be exerted by procaspase-9 itself since it was shown that caspase-9 can be active without proteolytic processing (Stennicke et al., 1999) . Interestingly, we demonstrated that the protective role of caspase-9 observed in immortalized cells was also found in primary fibroblasts indicating that this alternative function has a physiological significance and is not the result of cell immortalization. Several studies report that different endogenous isoforms of caspase-9, either missing the catalytic site (Seol and Billiar, 1999; Srinivasula et al., 1999) or with an alternative Cterminus (Angelastro et al., 2001 ) inhibit apoptosis, suggesting that this protease is not only involved in proapoptotic pathways. However, in all these cases, the isoforms described act as dominant negative variants by interfering with the formation of a functional apoptosome and their protective activities are not inhibited by zVAD. Although the involvement of caspases has been widely established for most apoptotic processes, these proteases have also been shown to play nonapoptotic roles. Examples include the control of erythroblast differentiation by the caspase-mediated cleavage of GATA-1 (De Maria et al., 1999) and activation and proliferation of T cells (Alam et al., 1999; Kennedy et al., 1999) . These alternative functions could be related to a lower level of activity and/or to unknown mechanisms which would prevent caspases from causing apoptosis. This raises the possibility that the cleavage of some caspase substrates may induce antiapoptotic signals, rather than proapoptotic ones (Rudel and Bokoch, 1997; Mashima et al., 1999; Zhang et al., 1999) . In this way, several studies indicate that caspase activation and subsequent substrate cleavage do not irreversibly lead to apoptosis, and in some instances, protect cells from apoptosis (Eymin et al., 1999; Yang and Widmann, 2001 ). Thus, it was of great interest to investigate which substrate of caspase-9 could be involved in the inhibition of p53-dependent apoptosis of rat fibroblasts.
The tumor suppressor Rb is a target of caspase-9
We previously observed that p53 activation is accompanied by production of a truncated form of Rb protein (Rincheval et al., 1999) . The accumulation of this shorter form increases in the presence of Bcl-2 and is totally inhibited by zVAD. This led us to hypothesize that this truncated form is associated with cell survival and may be produced by caspase-dependent cleavage of Rb protein. Here, we demonstrate that the cleavage of Rb at a LExD site leads to production of a truncated form with a molecular weight of 76 kDa, termed p76 Rb . Several studies have shown that Rb is proteolytically cleaved by caspase-3 or caspase-7 (Janicke et al., 1996; Chen et al., 1997; Boutillier et al., 2000; Fattman et al., 2001 ), but to our knowledge nothing has been reported concerning cleavage by caspase-9. Here, we demonstrate that caspase-9 is able to cleave Rb specifically at the predicted LExD site to generate p76
Rb . This cleavage appears to be independent of apoptosome formation since the production of p76
Rb was detected in control cells in the absence of apoptosis and was increased by the antiapoptotic Bcl-2 protein. The caspase-9-dependent cleavage of nuclear Rb protein is in agreement with previous data showing that procaspase-9 can be localized and processed into discrete nuclear structures (Ritter et al., 2000) .
The p76
Rb truncated form of Rb antagonizes p53-mediated apoptosis Several studies report that Rb is cleaved at the Cterminal caspase-consensus site DEAD 886 when cells are induced to die, but few studies actually point to a role for the corresponding p100 fragment in apoptosis. In fact, apoptosis seems to correlate better with the disappearance of full-length Rb than with the accumulation of p100 (Janicke et al., 1996) , a notion which was supported by the well-described antiapoptotic function of full-length Rb (review in Harbour and Dean, 2000) . Similarly, controversial results fail to determine if the 68 kDa truncated form generated at DSID site plays a key role in apoptosis or is only a product of Rb degradation. Given the observations that caspase-9 on the one hand antagonizes p53-dependent apoptosis and on the other hand is able to cleave Rb, we postulated that the p76
Rb cleavage product might be one of the mediators of this protective pathway. We demonstrated that the p76
Rb form protects cells from p53-dependent apoptosis to the same extent as Bcl-2 or DN p53 mutants, whereas the full-length Rb fails to inhibit cell death. The protection afforded by p76
Rb is also observed in the presence of zVAD and the DN caspase-9 mutant, suggesting that the truncated p76
Rb protein exerts an antiapoptotic function downstream of caspase-9 to antagonize p53-dependent death. This suggests that the cleavage of Rb protein into the p76
Rb form is not a side effect of caspase activation during apoptosis, but plays a major active role in negatively regulating p53-dependent apoptotic process.
Both p53 and Rb play a central role in cellular growth regulation, differentiation and apoptosis. At the molecular level, Rb functions as an assembly factor in the nucleus through simultaneous binding to a number of partners, which are principally regulators of transcription, including E2F proteins. E2F family transcription factors are positive regulators of the cell cycle and they have been shown to mediate p53-dependent apoptosis in different cell types. All these activities are inhibited by binding of these factors to the A/B pocket of Rb (reviewed in Harbour and Dean, 2000) . Different Rb mediates caspase-9 antiapoptotic activity C Lemaire et al observations have led to a paradigm in which p53 and Rb can regulate each other, Rb playing an important role in the outcome -growth arrest vs apoptosis -of p53 activation. In this model, Rb acts as an antagonist of p53 activity and reduces p53-mediated apoptosis. The antiapoptotic function of p76
Rb described here is in agreement with such a model. Since the E2F1-bindingpocket is still present in p76 Rb , the more potent protective effect of this form could be explained by a higher affinity for E2F1 as compared to full-length Rb. The capacity of both p53 and Rb to interact with the same oncoprotein, namely MDM2, points to another possible level of regulation between these two tumour suppressors. MDM2 can bind to p53 and target it for degradation by the proteasome (Prives, 1998) . The binding of Rb to MDM2 in a Rb-MDM2-p53 trimeric complex overcomes the MDM2-dependent degradation of p53 and rescues p53 proapoptotic activity (Hsieh et al., 1999) . Since the Rb-binding site of MDM2 (residues 792-928) is still present in p76
Rb after caspase-9 cleavage, the protective activity of p76
Rb against p53-mediated apoptosis could result from its ability to compete Rb in the formation of the trimeric complex with MDM2 and p53. In such a complex, apoptosis would be prevented by restoration of MDM2-mediated degradation of p53 or by a sustained inhibition of the proapoptotic transrepression function of p53. The balance between apoptosis or/and cell survival would therefore depend upon the formation of p76 Rb -MDM2-p53 vs Rb-MDM2-p53 complexes. Nevertheless, we cannot exclude that p76
Rb could present specific binding properties leading to the inhibition of other proapoptotic proteins. Elsewhere, p53 was shown to facilitate Rb cleavage in IL-3-deprived cells, pointing to the possibility that p53 regulates the activity of a caspase which cleaves Rb (Gottlieb and Oren, 1998) . This notion correlates with our results demonstrating that, in the presence of Bcl-2, p53 activation leads to an increase in caspase-9-mediated p76 Rb production. In conclusion, although the determination of the binding partners of p76
Rb and of the mechanisms by which p76
Rb protects cells remain to be elucidated, this study demonstrate for the first time that a truncated form of Rb plays a critical role in preventing p53-dependent apoptosis of fibroblasts, showing an autonomous function different from full-length Rb. Therefore, clarification of the role of the truncated p76
Rb form in tumor formation deserves further investigation and will allow greater understanding of the interplay between p53 and Rb in apoptosis regulation.
Materials and methods
Cell lines, cell culture and drugs
Isolation of RE and REtsAF cell line has been described previously (Petit et al., 1983) . Cells were cultured in Dulbecco's modified Eagle's medium (DMEM-F12, Invitrogen) supplemented with 100 mg/ml penicillin (Invitrogen), 100 U/ml streptomycin (Invitrogen), 1% Glutamax (Invitrogen) and 10% foetal calf serum (Invitrogen), under 5% CO 2 /95% air.
Development of the REtsAF-Bcl-2 cell line, which expresses the human bcl-2 gene under control of tetracycline, has been previously described (Guenal et al., 1997; Rincheval et al., 1999) . The REtsAF-Bcl-2 cells were routinely maintained in presence of 2 mg/ml tetracycline to inhibit the expression of exogenous bcl-2. The caspase inhibitors zVAD-fmk, YVADfmk and LEHD-cmk, were obtained from Bachem Biochimie. Etoposide, STS, fluorescein diacetate (FDA) and ethidium bromide (EtBr) were purchased from Sigma.
Plasmids construction
Cloning of human bcl-2 was previously described (Guenal et al., 1997) . The cDNA encoding human Rb was subcloned from the Bluescript plasmid (p4.95BT, a gift from Dr TP Dryja, Harvard Medical School, Boston) between the SacIIBamH1 sites of the pTRE plasmid (Clonetech). The p76 
Assessment of cell viability, apoptosis and necrosis
Cells were washed with PBS and then double-stained with FDA (1 mg/ml) and EtBr (20 mg/ml) for 5 min at 371C. FDA, after being taken up by live cells, is cleaved by intracellular esterases, yielding green fluorescent fluorescein. We used the EtBr at a high concentration to allow uptake (even weakly) and staining of the nuclei of viable cells as previously described . Quantitative analysis of each population was performed by counting more than 500 cells, discriminated as viable (green fluorescence and weakly stained normal nucleus), apoptotic (strongly red condensed or fragmented nucleus) or necrotic (strongly red 'apparently normal' or patchly nucleus).
Cell transfections
REF and REtsAF cells were cultured on glass plates in 35 mm dishes. At 50-70% of confluence, the cells were transiently cotransfected with 1 : 4 ratios of GFP-encoding vector (p-EGFP-N2, Clonetech) and the vectors of interest (1 mg total DNA per dish), respectively. The DNA and LipofectAMINE PLUS TM reagent (Life Technologies) were mixed according to the manufacturer's recommendations. We transfected either the mutant p53 val135 (temperature sensitive at 39.51C, Martinez et al., 1991) in REtsAF cells or the mutant p53 ala143 (temperature sensitive at 371C, Friedlander et al., 1996) in REF cells or the nontemperature-sensitive mutant p53 phe132 (Malcomson et al., 1995) in STS-treated REtsAF cells (331C). The dominant negative mutants of caspases were kindly provided by Dr P Mehlen (Molecular and Cellular Genetic Center, Villeurbane, France). These DN mutants were obtained by mutating the active site cysteins to alanine via Quickchange strategy from Stratagene (Forcet et al., 2001) . Bcl-2 encoding vector was previously described (Guenal et al., 1997) . The pTRE plasmid was used as a control. At 24 h after transfections, REtsAF apoptosis was induced either by switching cells to 39.51C for 20 h or by incubation for 6 h in the presence of staurosporine (0.5 mM). Apoptosis of REF cells was induced either by etoposide (50 mg/ml, 24 h) or p76
Rb mediates caspase-9 antiapoptotic activity C Lemaire et al by staurosporine (0.5 mM, 6 h) treatment. When indicated in figures, zVAD was added to cultures at 100 mM. In each experiment, the rate of transfection efficiency was about 50%. The percentage of viable and apoptotic cells were counted in the population of GFP-positive cells on an epifluorescence microscope according to their morphological features. Photographs of cells were taken using a Nikon TMS microscope equipped with a Nikon F601 camera.
Western blot analyses
Attached and floating cells were recovered, rinsed in cold PBS, and lysed in lysis buffer (50 mM HEPES-KOH pH 7.4, 250 mM NaCl, 1% NP-40, 5 mM EDTA, 0.5 mM DTT and a cocktail of protease inhibitors (Boeringher Manheim)) for 30 min at 41C, followed by 10 passages through a 25-gauge syringe. Proteins (80 mg) were separated by SDS-PAGE (15% acrylamide/0.2% bisacrylamide for caspase-9, Bax, p21 detection or 7.5% acrylamide/0.1% bisacrylamide for Rb and Mdm2 detection) and transferred to PVDF membranes (Millipore). After overnight incubation at 41C with either anti-caspase-9 rat specific (Ozyme), anti-human Rb (clone G3-245, Pharmingen), monoclonal anti-PARP (clone C2-10, R&D Systems), anticaspase-3 (clone H277), anti-Bax (N20), anti-p21 (C19) or anti-Mdm2 (SMP14) antibodies (Santa Cruz Biotechnologies), proteins were detected by using the ECL method according to the manufacturer's instructions (Amersham).
In vitro Rb cleavage assay
Purified human recombinant Rb protein and caspases were purchased from Gentaur Molecular Products and Biomol, respectively. In vitro cleavage of Rb was performed by incubating 50 U of one of the recombinant caspases (caspase-2, -3, -7, -8, -9, -10) with 10 ng of recombinant Rb in caspase buffer (20 mM PIPES, pH 7.2, 100 mM NaCl, 1% CHAPS, 10% sucrose) for 2 h at 371C. The production of Rb fragments was analysed by Western blotting using either the G3-245 antibody (Pharmingen) raised against the Rb N-terminus or the Ab-6 antibody (Oncogene) raised against the A/B pocket of Rb. For in vitro cleavage of Rb by cell lysates, REtsAF-Bcl-2 cells were incubated for 16 h at 33 or 39.51C in the absence or presence of either zVAD-fmk (100 mM), or YVAD-fmk (100 mM), or LEHD-cmk (200 mM). Cells were then lysed in lysis buffer (see above) for 30 min at 41C. Cell lysates corresponding to 50 mg of proteins was added to 10 ng of recombinant Rb and incubated at 371C for 4.5 h. The reaction was terminated by adding sample buffer and boiling immediately. Rb products were analysed by Western blotting using the G3-245 antibody.
